当前位置: »论坛 › 科研专区 › 文献互助› PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-C ...

[ASH] PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies

求助已关闭

HarryPan 发表于 4 天前 | 显示全部楼层 |阅读模式

悬赏10积分

期刊：Blood

文献作者：Haihui Lu; Adwait Oka; Michelle Coulson; Joseph Ryan Polli; Kimberly Aardalen; Melissa Ramones; Dana B Walker; Ana Carrion; Dylan Alexander; Matthieu Klopfenstein; Masaki Akiyama; Francesca Rucci; Brian Granda; Alessandro Pastore

出版日期：2022-11-15

DOI号：10.1182/blood-2022-168904

下载链接：https://ashpublications.org/bloo ... -CD19-Anti-CD3-Anti

文献链接：https://doi.org/10.1182/blood-2022-168904

当前文献来源于 American Society of Hematology。

备注信息：

使用道具捐赠获取积分应助有误反馈

全部回复0 显示全部楼层

发表回复

HarryPan Lv.4

VIP会员

发布
回复
积分
2200

[ASH] PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies

发表回复

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[ASH] PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies 一键复制

发表回复

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[ASH] PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies